Cannabis stocks were trading mostly up Wednesday morning after Piper Jaffray started coverage of the group.
Piper Jaffray's Michael Lavery said in his initiation note that the cannabis industry is in its early stages, with "much to learn," according to CNBC.
The long-term growth opportunities are "significant" as the global cannabis market benefits from a transition from illicit trade to legal sales, along with usage in the medical space, in the analyst's view.
Tilray boasts the right structure for long-term global growth from its global existing relationships across the medical and beverage sectors, according to Piper Jaffray.
On the other hand, Canopy Growth's existing large size can be leveraged to create near-term momentum that should generate the necessary resources to help fuel long-term opportunities, Lavery said.
Cannabis investors can't miss the Benzinga Cannabis Capital Conference, the No. 1 networking event for institutional capital and leading cannabis companies. Secure your tickets here before they run out.
Why It's Important
The legalization of cannabis for recreational use in Canada, coupled with the medical market in Europe and CBD-infused products in the U.S. created a $15 to $50-billion market, Lavery said. The global cannabis market has the long-term potential to increase tenfold to $250 billion to $500 billion in size, he said.
The cannabis sector is also attractive to investors as governments worldwide are drawn to the drug as a new source of tax revenue, the analyst said.
Legalization of cannabis in the U.S. could be a hot topic ahead of the 2020 presidential election, according to Piper Jaffray. Encouragingly, both Democrats and Republicans "could conceivably co-opt the issue" of legalization, which would likely create new inflows of capital and the potential for M&A activity, the sell-side firm said.
A New Tool To Track The Cannabis And Crypto Markets
Constellation Brands Beats Q3 Earnings Estimates, But Stock Sinks On Canopy Growth-Related Guidance Cut
Latest Ratings for CGC
|Jan 2019||PiperJaffray||Initiates Coverage On||Overweight|
|Sep 2018||Benchmark||Initiates Coverage On||Buy|
|Aug 2018||Canaccord Genuity||Upgrades||Hold||Speculative Buy|
View More Analyst Ratings for CGC
View the Latest Analyst Ratings
See more from Benzinga
- FDA: CBD Products Mostly Illegal
- 5 Risks Cannabis Investors Need To Understand
- Cowen: What The Sandoz Deal Means For Tilray Investors
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.